About EAS
Society & Governance
Publications
Collaborations & Outreach
Education
Academy
FAQ
Become a member

Search for:

About EAS
Society & Governance
Publications
Collaborations & Outreach
Education
Academy
FAQ
Become a member

Test 1 of 0

Module 3: Post lecture test Copy

Carmel Hayes December 18, 2023

Time limit: 0

Test Summary

0 of 4 Questions completed

Questions:

Information

You have already completed the test before. Hence you can not start it again.

Test is loading…

You must sign in or sign up to start the test.

You must first complete the following:

Results

Test complete. Results are being recorded.

Results

0 of 4 Questions answered correctly

Your time:

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

1
2
3
4

Current
Review
Answered
Correct
Incorrect

Question 1 of 4
1. Question
In the FOURIER-OLE study assessing the safety of prolonged PCSK9 inhibition by Evolocumab, the maximum follow up was:
- 5.5 years
- 2.2 years
- 8.4 years
- 10.2 years
Correct
Incorrect
Question 2 of 4
2. Question
Which of the following related to the use of omega-3 fatty acids in cardiovascular (CV) prevention is correct?
- Low dose omega-3 fatty acids reduce CV events
- High dose EPA reduces CV events
- High dose EPA+DHA reduce CV events
- High dose DHA reduces CV events
Correct
Incorrect
Question 3 of 4
3. Question
Which one of the following related to LDL-C lowering effect of medications is correct?
- Combination therapy with high intensity statin+ezetimibe+PCSK9 monoclonal Ab will reduce LDL-C up to 75%
- Bempedoic acid+ ezetimibe fixed dose combination on top of maximally tolerated statins will reduce LDL-C 36%
- Inclisiran will reduce LDL-C by 62%
- Obicetrapib in high dose will reduce LDL-C 30%
Correct
Incorrect
Question 4 of 4
4. Question
Statin associated muscle symptoms in observational studies (PRIMO Study) in patients receiving high dose statins are seen in:
- 10-20%
- 20-30%
- 30-40%
- 40-50%
Correct
Incorrect

Cookies

We use cookies. If you think that's OK, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".

Settings Accept all

Cookies

Choose what kind of cookies to accept. Your choice will be saved for one year. You can change your settings from our Cookie Policy page.

Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience and analytics
If you refuse these cookies, some functionality, like the ability to view videos, will disappear from the website.
Marketing
By sharing your interests and behaviour as you visit our site, you increase the chance of seeing personalised content and offers.

Save Accept all

Report

There was a problem reporting this post.

Offensive Contains abusive or derogatory content

Inappropriate Contains mature or sensitive content

Misinformation Contains misleading or false information

Suspicious Contains spam, fake content or potential malware

Harassment Harassment or bullying behavior

Other

Report note

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

See blocked member's posts
Mention this member in posts
Invite this member to groups
Message this member
Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .